Management of Pregnancy induced hypertension (PIH) by Methyldopa versus labetalol - A randomized controlled trial
European Journal of Molecular & Clinical Medicine,
2023, Volume 10, Issue 1, Pages 3271-3276
AbstractPregnancy-related hypertension can alter the outcomes of pregnancy if left unmanaged. The complications associated with pregnancy-related hypertension include pre-eclampsia and eclampsia. Various medicines are available that can avoid these complications and lead to better outcomes of pregnancy. Material and Methods: The study was conducted on 250 patients with pregnancy-induced hypertension (PIH) that were prospectively enrolled over two years at a tertiary healthcare facility. After randomization of the patients into two groups, methyldopa or labetalol was administered to patients. The difference between the two groups was evaluated for the mode of labour, delivery, perinatal mortality, mean birth weight, Apgar score and neonatal intensive care (NICU) admissions. Result: There was no significant difference observed in the mode of labour, delivery, perinatal mortality, mean birth weight, Apgar score and neonatal intensive care (NICU) admissions between the patients undergoing management with methyldopa or labetalol. Conclusion: Overall, labetalol was found to have slightly better and safer outcomes for both the mother and the fetus in comparison to methyldopa.
- Article View: 6
- PDF Download: 29